# DESCRIPTION

## FIELD OF THE INVENTION

- define field of invention

## BACKGROUND OF THE INVENTION

- describe cancer statistics
- explain cancer biology
- discuss limitations of existing methods

## SUMMARY OF THE INVENTION

- describe CoAA amplification discovery
- outline embodiments for treatment, detection, and screening

## DETAILED DESCRIPTION OF THE INVENTION

### I. Compositions for the Treatment of Cancer

- introduce CoAA gene amplification in cancer
- describe CoAA gene structure and alternative splicing
- motivate CoAA as a target for cancer treatment
- summarize CoAA gene amplification in lung cancer
- describe CoAA protein overexpression in cancer cells
- introduce inhibitory nucleic acids for CoAA amplicon
- describe peptide nucleic acids as inhibitory nucleic acids
- introduce aptamers as inhibitory nucleic acids
- introduce antisense nucleic acids for CoAA and splice variants
- define compositions for cancer treatment
- describe peptide nucleic acids specific to CoAA or splice variants
- introduce aptamers that specifically bind to CoAM
- describe siRNA to CoAA or alternative splice variants
- detail characteristics of siRNA
- describe methods for designing siRNA
- introduce antibodies specific for CoAM
- describe structure of antibodies
- detail variable and constant domains of antibodies
- describe complementarity determining regions (CDRs)
- explain antibody diversity
- discuss conservative and non-conservative changes to antibody sequences
- describe types of antibodies (polyclonal, monoclonal, humanized, etc.)
- introduce chimeric and humanized antibodies
- describe cells that produce antibodies (hybridomas)
- introduce anti-CoAM antibody operably linked to cell penetrating peptide
- describe function of cell penetrating peptide

### II. Diagnostics for and Methods of Diagnosing Cancer

- introduce diagnostic assays for cancer
- establish baseline values for CoAM expression
- determine expression levels of CoAA splice variants
- define differential expression of genes
- quantify gene expression using various techniques
- use antibodies for in situ imaging and detection
- apply in situ hybridization for tissue arrays
- use diagnostic assays for prognosis and therapeutic efficacy

### III. Screening Assays

- use CoAA or splice variants in screening assays
- screen for agents that modulate cancer phenotype
- define modulation of gene expression or protein activity
- describe high throughput screening techniques
- outline expression profiles for monitoring gene expression
- immobilize CoAA or splice variant probes to solid supports
- describe solid supports and their configurations
- add candidate bioactive agent prior to analysis
- define candidate bioactive agent or drug candidate
- describe preferred embodiments of candidate agents
- outline assay components and labeling
- describe detection methods for labeled compounds
- outline hybridization conditions and stringency control
- describe reaction components and reagents
- outline data analysis for expression levels and changes
- screen for agents that alter biological function of CoAA gene product
- describe binding assays and activity assays
- outline binding assays with purified CoAA or splice variant proteins
- describe competitive binding assays and displacement methods
- outline differential screening for bioactive agents

### IV. Pharmaceutical Compositions and Methods of Treatment

- define pharmacological activity
- describe administration of compounds
- introduce bioactive agents
- describe delivery of agents
- outline routes of administration
- describe pharmaceutical compositions
- discuss manufacturing processes
- formulate compositions for injection
- formulate compositions for oral administration
- describe dragee cores and coatings
- formulate compositions for inhalation
- describe parenteral administration
- formulate depot preparations
- describe co-solvent systems
- discuss liposomes and emulsions
- estimate therapeutically effective doses
- determine dosage ranges
- describe dosage forms and regimens
- outline packaging and labeling
- describe methods of treatment
- provide examples of treatable cancers

## EXAMPLES

### Alternative Splicing of CoAA Gene Transcripts

- describe CoAA gene structure and alternative splicing
- identify CoAR splice variant and its transcriptional activity

### Switched Alternative Splicing of CoAA and CoAM During P19 Stem Cell Differentiation

- introduce P19 stem cell line and its differentiation
- analyze CoAA and CoAM expression during differentiation
- detect switched expression of CoAA and CoAM during EB formation
- confirm switched expression using real-time PCR analysis
- analyze expression of differentiation markers
- detect CoAM protein expression in EB cavity
- suggest CoAM regulates target gene expression during cavitation

### Decreased CoAA and Increased CoAM Induce Sox6 Expression in P19 Cells

- test CoAA and CoAM regulation of differentiation
- show CoAA and CoAM regulate Sox6 expression

### Construction of CoAA Minigene

- design CoAA minigene to prevent functional CoAA and CoAM
- construct CoAA minigene with intact splicing junctions
- evaluate CoAA minigene under CMV promoter
- analyze CoAA minigene under CoAA basal promoter with cis-regulatory sequences

### Example 5

- perform chromatin immunoprecipitation
- test alternative splicing of CoAA minigene
- analyze results of PSF and p54nrb overexpression
- discuss role of cis-regulating sequence in alternative splicing
- perform ChIP analysis with various antibodies
- analyze interactions of protein complexes with CoAA promoter
- examine upstream cis-regulating sequence in regulating alternative splicing
- compare CoAA minigenes with different lengths of cis-regulating sequence
- analyze expression of CoAA and CoAM during RA-induced EB formation
- discuss linked transcription rate and alternative splicing regulation
- analyze CoAA C-terminal repeats using ScanProsite program
- identify proteins with similar YxxQ motifs
- perform FISH analysis on human cancer tissues
- analyze CoAA gene amplification in various human cancers
- discuss independent CoAA amplification from CCND1
- map CoAA amplicon
- identify amplicon boundaries
- analyze CoAA protein expression
- examine CoAA mRNA expression
- generate CoAA mutants
- perform transformation assay
- conduct transient transfection and RNA interference
- analyze CoAA promoter activity
- evaluate consequence of sequence loss
- construct serial deletion of CoAA upstream sequences
- examine CoAA protein regulation of its own promoter
- propose model for CoAA deregulation in cancer
- illustrate model for CoAA overexpression

